Claims
- 1) A composition for treatment of a bacterial infection of an upper respiratory tract, comprising:
an effective amount of at least one lytic enzyme produced by a bacteria being infected with a bacteriophage specific for said bacteria; and a carrier for delivering said at least one lytic enzyme to a mouth, throat, or nasal passage.
- 2) The composition according to claim 1, wherein said bacteria being treated is selected from the group consisting of Streptococcus pneumoniae and Hemophilus influenza.
- 3) The composition according to claim 2, wherein said bacteria being treated is Streptococcus pneumoniae.
- 4) The composition according to claim 2, wherein said bacteria being treated is Hemophilus influenza.
- 5) The composition according to claim 1, wherein said carrier is selected from the group consisting of a candy, chewing gum, lozenge, troche, tablet, a powder, an aerosol, a liquid and a liquid spray.
- 6) The composition according to claim 1, wherein said composition further comprises a buffer that maintains pH of the composition at a range between about 4.0 and about 9.0.
- 7) The composition according to claim 6, wherein the buffer maintains the pH of the composition at the range between 5.5 and 7.5.
- 8) The composition according to claim 6, wherein said buffer comprises a reducing reagent.
- 9) The composition according to claim 8, wherein said reducing reagent is dithiothreitol.
- 10) The composition according to claim 6, wherein said buffer comprises a metal chelating reagent.
- 11) The composition according to claim 10, wherein said metal chelating reagent is ethylenediaminetetracetic disodium salt.
- 12) The composition according to claim 6, wherein said buffer is a citrate-phosphate buffer.
- 13) The composition according to claim 1, further comprising a bactericidal or bacteriostatic agent as a preservative.
- 14) The composition according to claim 1, wherein said lytic enzyme is lyophilized.
- 15). The composition according claim 1, wherein said at least one lytic enzyme is present in a concentration of about 100 to about 100,000 active enzyme units per milliliter of fluid in the wet environment of the nasal or oral passages.
- 16) The composition according to claim 15, wherein said at least one lytic enzyme is present in a concentration of about 100 to about 10,000 active enzyme units per milliliter of fluid in the wet environment of the nasal or oral passages.
- 17) The composition according to claim 1, wherein said composition is for a prophylactic treatment of the bacterial infection of the upper respiratory tract.
- 18) The composition according to claim 1, wherein said composition is for a therapeutic treatment of the bacterial infection of the upper respiratory tract.
Parent Case Info
[0001] The following application is a continuation-in-part of Ser. No. 09/497,495 filed Apr. 18, 2000 which is a continuation of Ser. No. 09/395,636 filed Sep. 14, 2000, now U.S. Pat. No. 6,056,954 which is a continuation-in-part of U.S. patent application Ser. No. 08/962,523, filed Oct. 31, 1997, now U.S. Pat. No. 5,997,862.
Continuations (3)
|
Number |
Date |
Country |
Parent |
10083142 |
Feb 2002 |
US |
Child |
10720266 |
Nov 2003 |
US |
Parent |
09654482 |
Sep 2000 |
US |
Child |
10083142 |
Feb 2002 |
US |
Parent |
09395636 |
Sep 1999 |
US |
Child |
09497495 |
Apr 2000 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09497495 |
Apr 2000 |
US |
Child |
09654482 |
Sep 2000 |
US |
Parent |
08962523 |
Oct 1997 |
US |
Child |
09395636 |
Sep 1999 |
US |